David Glazier, MD
Urology · Richmond, VANPI 1427011329
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,700 of the $7,425 with a category attached, or 76.8%. It is spread thinly across 37 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,186 and has fallen 62.8% since, to $814 in 2025.
Across 201 payments — averaging $36.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Caldera Medical, Inc$1K
- AbbVie$1K
- Intuitive Surgical$781
- Johnson & Johnson$551
- Dendreon Pharmaceuticals LLC$228
- plus $2K from 31 others
Across 18 payments — averaging $5699.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$103K
What the payments were for
- Consulting fees$5007%
- Travel & lodging$1,22617%
- Food & beverage$5,70077%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 8 | $1,357 |
| Caldera Medical, Inc | 10 | $1,217 |
| AbbVie(2 entities) | 28 | $1,028 |
| Intuitive Surgical | 12 | $781 |
| Johnson & Johnson | 40 | $551 |
| Dendreon Pharmaceuticals LLC | 9 | $228 |
| Bayer | 9 | $208 |
| Blue Earth Diagnostics | 8 | $203 |
| Boston Scientific | 3 | $182 |
| Medtronic | 1 | $132 |
| Urogen Pharma, Inc. | 5 | $127 |
| Astellas Pharma US Inc | 6 | $126 |
| Endo USA, Inc. | 5 | $120 |
| Novartis | 6 | $117 |
| Sumitomo Pharma America, Inc. | 5 | $117 |
| Merck | 5 | $108 |
| Amgen | 5 | $80 |
| Endo Pharmaceuticals Inc. | 4 | $74 |
| Calyxo, Inc. | 1 | $63 |
| Antares Pharma, Inc. | 3 | $61 |
| Progenics Pharmaceuticals, Inc. | 3 | $59 |
| Sun Pharmaceutical Industries Inc. | 2 | $55 |
| Ferring Pharmaceuticals Inc. | 2 | $53 |
| Myovant Sciences Inc. | 2 | $43 |
| Ambu Inc. | 2 | $39 |
| Photocure Inc | 2 | $36 |
| Teleflex LLC | 2 | $36 |
| Urovant Sciences Inc | 2 | $36 |
| Pfizer | 2 | $32 |
| Rochester Medical Corporation | 2 | $31 |
| Halozyme Inc | 1 | $25 |
| AstraZeneca | 1 | $20 |
| Procept Biorobotics Corporation | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
| Accord Healthcare, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$986
- ALTIS$928
- Da Vinci Surgical System$473
- RESTORELLE$377
- BOTOX COSMETIC$250
- INTERSTIM$132
- GENERAL FEMALE SUI$121
- Vertessa$111
How this compares
$7,425 in reported general payments places this provider in the 70th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 74 | $60,138 |
| GemtesaVibegron | 22 | $14,985 |
| Tolterodine Tartrate ErTolterodine Tartrate | 166 | $14,523 |
| Trospium Chloride | 94 | $5,021 |
| Estradiol | 48 | $2,923 |
| NitrofurantoinNitrofurantoin Macrocrystal | 54 | $1,601 |
| Tamsulosin Hcl | 112 | $1,397 |
| CefuroximeCefuroxime Axetil | 54 | $1,370 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 84 | $1,359 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $861 |
| Ciprofloxacin Hcl | 111 | $437 |
| Cephalexin | 15 | $226 |
| Solifenacin Succinate | 13 | $174 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $130 |
| Cefdinir | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $126 | $60,13874 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $117 | $14,98522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 300 urology providers in Virginia.
Other urology in Richmond
- Lonny GreenRichmond$59K
- Anthony SliwinskiRichmond$47K
- Blake MooreRichmond$42K
- John DelisioRichmond$39K
- Kinloch NelsonRichmond$25K
- Charles SeaburyRichmond$24K
- Jeffrey LouRichmond$24K
- David MillerRichmond$20K
- James RatliffRichmond$19K
- Andrew ColhounRichmond$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.